New drug combo shows promise in early AML trial
NCT ID NCT04190550
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new drug called navtemadlin (KRT-232) combined with standard chemotherapy (cytarabine and idarubicin) in adults with newly diagnosed acute myeloid leukemia (AML). The goal is to find the safest dose and see how well the combination works. About 24 participants will receive the treatment to help control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Laura and Isaac Perlmutter Cancer Center at NYU Langone
New York, New York, 10016, United States
-
Los Angeles General Medical Center
Los Angeles, California, 90033, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
University of Maryland/Greenebaum Cancer Center
Baltimore, Maryland, 21201, United States
-
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104, United States